Teva (NYSE:TEVA) this week launched its generic version of Mylan‘s (NSDQ:MYL) EpiPen auto-injector and announced that it would sell the emergency allergy therapy for $300 – the same price as Mylan’s own generic EpiPen product.
The price for Teva’s product inspired some head-scratching among patient advocates and healthcare professionals. After all, when the FDA first approved Teva’s generic EpiPen, the agency highlighted the notion that boosting competition with generics would ultimately make the product more accessible to a general population. But, at the same price as Mylan’s discounted EpiPen, some are wondering how Teva’s product will reach patients who couldn’t afford Mylan’s device.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva launches generic EpiPen at the same price as existing device appeared first on MassDevice.
from MassDevice https://ift.tt/2zyTCZ6
Cap comentari:
Publica un comentari a l'entrada